Abstract Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an “optimal” donor in the modern era are not well defined. Historically, donor-recipient…
ABSTRACT Regimens combining calcineurin inhibitors with methotrexate or mycophenolate have been the backbone for graft-versus-host disease (GVHD) prophylaxis. Early studies highlighted a delicate dose–response balance. The inclusion criteria comprised randomized clinical trials…
Patients who receive hematopoietic stem cell transplants are at risk of developing graft-versus-host disease (GVHD), where the immune cells descended from the transplanted stem cells attack the transplant recipient’s own tissues. Acute GVHD (aGVHD) is often treated with…
Key Points aGVHD causes loss of gastric stem cells, G-cells, and PCs, leading to increased gastric pH. Pentagastrin therapy repairs stem cell and PC deficits, reverses pH changes, and reduces aGVHD damage, improving survival. Abstract Acute graft-versus-host disease (aGVHD) is a…
Satyajit Kosuri, MD, is a medical oncologist who treats adult patients with acute leukemia, myelodysplastic syndrome and myelofibrosis. He is an expert in stem cell transplantation (also known as bone marrow transplant) and leads the Graft-Versus-Host Disease (GVHD) Clinic, a program designed to prevent and treat GVHD, a complication of allogeneic stem cell transplant. His clinical research focuses on improving patient access to transplant through the use of alternative donor strategies and the use of novel immune therapies in these diseases. His main passion is guiding his patients through
The clinical impact of immunosuppression termination (IST) after allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains to be fully elucidated. This study was aimed at assessing the impact of IST within 2 years after transplantation on subsequent clinical…
Despite concerns about the toxicity of allogeneic hematopoietic cell transplantation (alloHCT) in older patients, prospective data characterizing prevalence or risk stratification for geriatric morbidity such as disability or frailty are limited. We prospectively assessed the…
Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (allo HCT) is essential for treatment planning; however, the parameters that define an "optimal" donor in the modern era are not well defined. Historically, donor-recipient human…
Patients with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood c